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BACKGROUND: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first
line in patients (pts) with metastatic breast cancer. Rare cases of nasal septum perforations have been reported. We report our
experience of nasal perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the
metastatic settings.
METHODS: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had
received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded
according to CTCAE.
RESULTS: Five nasal septum perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15mgkg
1 3 weekly. Three pts
were metastatic. Bevacizumab was associated with docetaxel (100mgm
2 every 3 weeks) in two pts and with weekly paclitaxel in
one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two
cases, nasal septum perforation occurred at the time of docetaxel treatment.
CONCLUSION: A high incidence of nasal septum perforation has been shown in pts with breast cancer receiving bevacizumab together
with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
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Angiogenesis is a hallmark of cancer. Among the angiogenesis
factors identified, vascular endothelial growth factor (VEGF) is a
crucial regulator of angiogenesis in normal and malignant tissues
(Plate et al, 1992; Ferrara and Alitalo, 1999). Bevacizumab is a
humanised monoclonal antibody directed against VEGF, which has
significant activity against several solid tumours. Bevacizumab in
association with paclitaxel or docetaxel has been approved as first
line in patients (pts) with metastatic breast cancer. A significant
benefit has been observed on relapse-free survival ((RFS) when
combined with paclitaxel and docetaxel; Miller et al, 2007; Miles
et al, 2009). Although not approved yet, bevacizumab has been
shown to give a statistically significant benefit on RFS when given
as a second line together with anthracyclines or capecitabine
(Brufsky et al, 2009). It is currently used in clinical studies in the
adjuvant or neoadjuvant setting. Observed toxicities of bevacizu-
mab in the first studies include hypertension, proteinuria, mild to
moderate bleeding, delayed wound healing and thromboembolic
events. Rare cases of nasal septum perforations have been reported
(Fakih and Lombardo, 2006; Traina et al, 2006; Ruiz et al, 2007;
Burkart et al, 2008; Marı ´n et al, 2009; Power and Kemeny, 2010).
We report our experience of nasal perforation in breast cancer pts
receiving bevacizumab and chemotherapy either in the adjuvant or
metastatic settings.
PATIENTS AND METHODS
Patients
Between 1 January and 31 December 2009, 70 pts received
bevacizumab every 3 weeks together with chemotherapy, 67
at a dose of 15mgkg
1 and 3 at 7.5mgkg
1. In all, 15 pts had
bevacizumab alone after the end of chemotherapy. After the
observation of the first nasal perforation cases, the clinical files of
all the pts who had received bevacizumab were reviewed. All of
the pts treated or having been treated with Bevacizumab were
referred to the ENT specialist for a nasal examination. Symptoms
potentially related like nasal obstruction, rhinorrhea, mucosal
crusting and epistaxis were looked for. The clinical charac-
teristics of the pts and the details of the treatments are given in
Table 1.
Methods
The first administration of bevacizumab was a 90min intravenous
infusion, which was followed by the chemotherapy regimen. The
second administration of bevacizumab lasted 60min and the
duration of the following ones was 30min. Bevacizumab dose was
15mgkg
1 except for three pts in a clinical study who received
7.5mgkg
1. Docetaxel was given at a dose of 100mgm
2 every
3 weeks during 2h, weekly Paclitaxel (90mgm
2) administration
lasted 1h. Capecitabine was given at a dose of 1500mg twice daily,
2 weeks out of 3.
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Evaluation Program, 2006).
Before each course, leukopenia, proteinuria and hypertension
were monitored and the worst grade observed during the courses
was considered, as well as other side effects.
Results
All 70 pts received bevacizumab for breast cancer. Median age was
54 years (range, 32–74 years). All pts were female. One pt. had
a history of chronic sinusitis before bevacizumab/chemotherapy.
In all, 52 (75%) were treated in the metastatic setting (12 first line,
27 second line and 13 had received more than two lines). In all,
12 pts were included in an adjuvant clinical study. Six received
bevacizumab with a neoadjuvant chemotherapy in a clinical study
too. In all, 15 pts received weekly paclitaxel, 36 docetaxel every
21 days, 1 capecitabine. All pts in clinical studies received
bevacizumab in combination with anthracyclines and then in
association with docetaxel.
Clinical characteristics of pts with nasal septum
perforation
Five nasal septum perforations were found in the 70 pts (7.14%;
Figure 1). At diagnosis, Bevacizumab was part of the treatment
of the five pts. Bevacizumab dose was 15mgkg
1 3 weekly in all
the pts. The median time between beginning of Bevacizumab
treatment and diagnosis of nasal septum perforation was 21 weeks
(range, 9–45 weeks). The median age of affected pts was 42 years
(range, 33–50 years). Three pts were metastatic and had received
previous chemotherapy in the adjuvant setting (anthracyclin based
for one and sequential anthracyclin then docetaxel for the others).
One of them had epistaxis and two of them developed mucosal
toxicities (grade1 or 2) in the adjuvant setting. Bevacizumab was
associated with docetaxel (100mgm
2 every 3 weeks) in two pts
and with weekly paclitaxel for one pt.
The last two pts received bevacizumab in combination with
anthracyclin and then taxanes in the adjuvant setting. In these two
cases, nasal septum perforation occurred at the time of docetaxel
association.
None of the pts developed hypertension or proteinuria. Related
toxicities were mucositis (stomatitis four pts, one grade2 and
three grade1), cutaneous (four pts, one grade1 and three grade2),
haematological (two neutropenia, one grade3 and one grade4) and
neurological (one dysesthesia grade2). All but one had epistaxis.
One pt. described disorders of nasal airflow and wheezing.
One had crusting and infection of nasal mucosa. The total dose
received at the time of nasal perforation diagnosis was 45, 105, 120,
150 and 225mgkg
1, respectively.
Bevacizumab was stopped in four pts after the diagnosis of nasal
perforation. In one pt, bevacizumab was continued because of a
very good clinical response. Patients with nasal septum perforation
were followed by the ENT specialist; up to now, no healing and no
extension was observed even in the pt who continued bevacizumab
treatment.
Clinical characteristics of pts without nasal perforation
Among the other pts who received bevacizumab and chemo-
therapy without nasal septum perforation, 15 pts died, all of
progressive disease. Nine of them had epistaxis. Only two had ENT
examination and no nasal septum perforation was diagnosed.
Among the 50 alive pts without nasal septum perforation, 41 pts
(82%) had epistaxis, 11 nasal crusting (Figure 2). Among the 27 pts
who had received previous chemotherapy, only 1 experienced
epistaxis (both with docetaxel and FEC) and 4 had mucosal
toxicity. In all, 48 had ENT examination.
A total of 30 pts out of 50 (60%) had mucosal toxicity
(13 grade1, 8 grade2 and 9 grade3). In all, 16 experienced
cutaneous toxicities (2 grade1, 8 grade2 and 6 grade3), 8 haemato-
logical toxicities (1 neutropenia grade3 and 7 grade4), 1 neuro-
logical toxicity (neuropathy grade3) and 1 cardiac event
Figure 1 Nasal septum perforation.
Figure 2 Nasal septum irritation.
Table 1 Clinical characteristics and details of treatments (70 patients)
Median age (min–max) 54 years (32–74)
Treatment setting
Neoadjuvant 6
Adjuvant 12
Metastatic 52
Number of previous lines of chemotherapy
01 2
12 7
X21 3
Regimen
Sequential anthracyclin/docetaxel + concomitant Bevacizumab
Neo adjuvant treatment 6
Adjuvant treatment 12
Docetaxel/Bevacizumab 37
Paclitaxel/Bevacizumab 14
Capecitabine/Bevacizumab 1
Bevacizumab as maintenance treatment 14
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Hypertension appeared at least at one time for 15 pts (grade1–2;
TA max 196/96; 30%).
Response to treatment
Response to treatment could be assessed in pts with metastatic
disease and in pts in the neoadjuvant setting. The response rates
were in first-line metastatic 7 partial responses (PRs); in second
line 2 complete responses (CRs), 15 PRs, 1 stable disease and
1 progression; after the second line, 2 CRs, 5 PRs and 1 progres-
sion. In all, two CRs and four PRs were observed in pts receiving
a neoadjuvant treatment.
DISCUSSION
This study reports our experience of nasal septum perforations
in breast cancer pts receiving bevacizumab and chemotherapy.
The incidence rate of nasal septum perforation was 7.14%. To our
knowledge, such a high rate has never been reported and might
be underestimated.
To our knowledge, only eight cases of nasal septum perforation
in bevacizumab-treated pts have been reported. The clinical
characteristics are summarised in Table 2. There are two cases of
breast cancer, five cases of colon cancer and one case of ovarian
cancer.
Nasal septum perforations with bevacizumab can thus occur
independently of the chemotherapy regimen (LV5FU2, FOLFOX,
paclitaxel) and sometimes during maintenance therapy with
bevacizumab. The total dose exposure before perforation varies
from 30 to 150mgkg
1.
The management is not clearly defined. In some cases bevacizu-
mab was discontinued. We do not know whether bevacizumab must
be stopped or which treatment should be proposed.
ENT monitoring and evolution of the perforation (size, long
term symptoms,y) are not detailed. In one case, plastic surgery
was performed.
Nasal septum consists of an osteochondral skeleton covered with
periosteum, perichondrum and mucosa. Its vascularisation depends
on several arteries (Legent et al, 1999; Steff, 2000–2001): the spheno-
palatine artery, a branch of the external carotid artery, the anterior
and posterior ethmoidal artery, branches of the internal carotid
artery. The anterior part of the nasal septum is highly vascularised
with arterial anastomoses. Risk factors for nasal septum perfora-
tions are traumatic injury, intranasal drug use, inhaled irritants,
inflammatory diseases and infections. Cocaine and other similar
drugs are potent vasoconstrictors, which if applied on the mucosa
of the nasal septum may cause intense inflammation, congestion
and bacterial colonisation (Lorenzi et al, 1997). This can lead to
ischaemic necrosis of the septal cartilage. Inhalation of chemical
irritants (chromium, dust and metal oxide.) causes irritation and
severe inflammation of the nasal mucosa responsible for ulcerations,
which can lead to perforation of the nasal septum.
Nasal septum infection weakens the nasal mucosa and then
can be responsible for perforation. Various systemic diseases can
also cause nasal septal perforation (Wegener’s granulomatosis,
systemic lupus erythematosus, antiphospholipid syndrom,
sarcoidosisy; Vignes et al, 2002). Mechanisms involved are
ischaemic, infections and inflammatory.
Younger and Blokmanis (2005) also noted that 3% of NSP may
be completely asymptomatic and discovered during a consultation
for another reason.
In our pts receiving antiangiogenic therapy and chemotherapy,
several specific mechanisms could be involved. First, mucositis
induced by chemotherapy may weaken nasal mucosa. Nasal irrita-
tion due to chemotherapy induced mucositis and/or bevacizumab
may induce mucosal breaks and ulcerations. These irritations can be
increased by frequent nose blowing and mechanical trauma.
Neutropenia frequently associated with chemotherapy enhance the
risk of local infection. Bevacizumab decreases normal tissue repair.
Bleeding could be seen because of the effect of bevacizumab in wound
healing. The inhibition of VEGF can induce a loss of capillaries by
apoptosis of endothelial cells, which causes tissue necrosis. Cartilage
is not vascularised. The trophicity is maintained by factors from
capillaries of mucosa via a terminal vascularisation. In the weakened
mucosa, the trophicity of the cartilage might no longer be obtained.
Finally, in our study, bevacizumab was associated with taxanes
in most cases. Several studies have shown the antiangiogenic
action of taxanes (Belotti et al, 1996; Hotchkiss et al, 2002; Grant
et al, 2003). Docetaxel appears to be more potent than Paclitaxel
(Grant et al, 2003). Endothelial cells seem to be 10–100-fold
more sensitive to taxanes than tumour cells (Grant et al, 2003).
Furthermore, two cases of nasal septum perforations have already
been described with Docetaxel alone in pts without risk factors
(Tan et al, 2006). A case of thrombotic microangiopathy following
Table 2 Previous cases reported
Cases Regimen Symptoms Management
Fakih and
Lombardo (2006)
Man, 53 years, metastatic
colon cancer
FOLFOX + Bevacizumab Nasal mucositis, occasional
epistaxis
Not discussed
Traina et al (2006) Women, 54 years,
metastatic breast cancer
Paclitaxel + Bevacizumab Rhinorrhea, nasal irritation,
occasional epistaxis, alopecia
of the nasal passage
Discontinuation of Bevacizumab + local
supportive therapy
Ruiz et al (2007) Man, 53 years, metastatic
colon cancer
LV5FU2 + Bevacizumab Occasional epistaxis + nose
pain + fungal infection
Discontinuation of Bevacizumab +
surgical excision of macroscopic
pathological tissue + antifungal
treatment
Burkart et al (2008) Woman, 52 years,
metastatic ovarian cancer
Bevacizumab Epistaxis Local supportive therapy + observation
Marı ´n et al (2009) Woman, 39 years,
metastatic breast cancer
Paclitaxel + Bevacizumab None No treatment Bevacizumab
discontinued for progression disease
Power and Kemeny
(2010)
Woman, 68 years,
metastatic colon cancer
FOLFOX + Bevacizumab Running nose, intermittent
epistaxis
Local supportive therapy +
discontinuation of Bevacizumab and
resuming at progressive disease
Man, 40 years, metastatic
colon cancer
LV5FU2 + Bevacizumab Nasal pain, rhinorrhea,
intermittent epistaxis
Local supportive therapy
Man, 35 years, metastatic
colon cancer
FOLFOX + Bevacizumab then
FOLFIRI + Bevacizumab
Intermittent epistaxis, nasal
congestion, crusting, whistling
sound on nasal inspiration
Local supportive therapy Bevacizumab
discontinued due to pulmonary
embolus
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endothelial toxicity of taxanes might explain potentialisation of
bevacizumab by taxanes in terms of efficiency, but also of toxicity
including nasal septum perforation. To our knowledge, no other
cases of nasal septum perforation with chemotherapy alone have
been reported.
A high incidence of nasal septum perforation has been shown in
pts with breast cancer receiving bevacizumab. Many questions
remain about the prevention and the management of nasal
septum perforation. A collaboration with ENT specialist is needed.
Whether or not bevacizumab should be stopped remains a matter
of debate. In the clinical practise, indication of antiangiogenic
therapy in breast cancer is increasing and many pts are concerned,
and clinicians must be aware of this side effect. ENT examinations
must be systematically performed in all pts receiving bevacizumab,
at least together with taxanes.
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